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Confirming Vertical Fetal Infection With
Coronavirus Disease 2019
Neonatal and Pathology Criteria for Early Onset and Transplacental Transmission of
Severe Acute Respiratory Syndrome Coronavirus 2 From Infected Pregnant Mothers
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Luisa Patanè, MD
 Increasing numbers of pregnant women with coronavi-
rus disease 2019 are being reported around the world. The
majority of neonates delivered to pregnant women
infected with severe acute respiratory syndrome corona-
virus 2 have been negative for the virus, but a small
number have tested positive for infection. It is important to
determine whether vertical transmission of coronavirus
disease 2019 occurs and the mechanisms for its develop-
ment. Based on a number of clinical and laboratory
findings, it has been suggested that transplacental trans-
mission may be occurring, but a method to confirm this is
necessary. This communication analyzes and evaluates the
covariables that have been discussed as potential indica-
tors of vertical and, specifically, intrauterine transmission,
including the timing of onset of neonatal illness, neonatal
viral test positivity, neonatal antibody testing for immuno-
globulin (Ig) G and IgM, and viral analysis of swabs of
whole specimens of placental tissue. None of these
methods can provide confirmatory evidence that infection
developed prior to labor and delivery, or that transplacen-
tal transmission occurred. This commentary proposes that
diagnosis of early-onset neonatal coronavirus disease 2019
infection should be limited to neonates with positive
reverse transcription polymerase chain reaction testing for
severe acute respiratory syndrome coronavirus 2 within
the initial 72 hours of life. It also proposes that the
occurrence of intrauterine transplacental severe acute
respiratory syndrome coronavirus 2 among infected
mother-infant dyads be based upon identification of severe
acute respiratory syndrome coronavirus 2 in chorionic
villus cells using immunohistochemistry or nucleic acid
methods such as in situ hybridization. Evaluating placentas
from neonates with coronavirus disease 2019 using these
methods will be instrumental in determining the potential
role and prevalence of transplacental transmission of the
coronavirus.
(Arch Pathol Lab Med. 2020;144:1451–1456; doi:
10.5858/arpa.2020-0442-SA)
Following the introduction of a new virus into the humanpopulation, among the most important questions that
typically arise are what its effect will be on pregnant women
and whether it will be transmissible to the developing fetus.
This has been true with many emerging viral agents,
including hemorrhagic fever agents such as the filoviruses
(Ebola and Marburg viruses) and arenaviruses (Lassa virus),
retroviruses (HIV), hepeviruses (hepatitis E virus), and, most
recently, flaviviruses (Zika virus). All of these emerging viral
infections have been shown to be capable of intrauterine
maternal-fetal transmission, often, and in some cases
typically, with disastrous results. In addition, 2 pathogenic
coronaviruses that were first identified in the last 20 years
have also caused this concern: the severe acute respiratory
syndrome coronavirus, causing severe acute respiratory
syndrome, and Middle East respiratory syndrome corona-
virus, causing Middle East respiratory syndrome. Although
these 2 coronaviruses resulted in maternal morbidity and
mortality as well as perinatal deaths, there were fortunately
no confirmed cases of intrauterine transmission identified.1,2
In December 2019 a new coronavirus was identified in
Wuhan, Hubei Province, China. It was the seventh
pathogenic member of the family Coronaviridae to be
reported to cause human disease. This new virus, termed
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) and producing a disease termed coronavirus disease
2019 (COVID-19), quickly spread from Wuhan throughout
China, then to neighboring countries, and ultimately
throughout the world, and was declared to be a pandemic
by the World Health Organization on March 11, 2020. One
of the major questions that arose early in the pandemic and
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has continued to be of significance is the ability of the virus
to be transmitted from the mother to her infant, termed
vertical transmission. In particular, it is important to
understand whether SARS-CoV-2 is being transmitted in
utero via the transplacental route. This communication
examines clinical, laboratory, and pathology methods for
determining whether transplacental maternal-fetal trans-
mission of COVID-19 is occurring, and how this process can
be evaluated and ultimately confirmed.
MECHANISMS OF VERTICAL TRANSMISSION
Viruses can be vertically transmitted from mother to infant
through 3 different mechanisms: intrauterine, intrapartum,
and postpartum routes.3 Intrauterine viral transmission can
occur via 2 major mechanisms: the hematogenous route and
the ascending route. The hematogenous route is character-
istic of most mother-to-fetus–transmissible viral agents. In
this mechanism, the virus is circulating in the maternal
bloodstream during pregnancy, enters the placenta via
maternal blood perfusing the placenta through the uterine
arterioles, and crosses the maternal-placental interface to
reach the fetal vessels in the chorionic villus tree and be
transmitted through the umbilical blood vessels to the
fetus.4,5 Hematogenous vertical transmission occurs with
such viruses as rubella, cytomegalovirus, parvovirus, Zika
virus, and Ebola virus, and requires that the virus be present
in the maternal blood—viremia. The ascending route of
intrauterine fetal infection occurs when microorganisms
present in the lower genital tract ascend the cervicovaginal
tract to reach the pregnant uterine cavity, from where they
breach the placental membranes and infect the amniotic
fluid. This mechanism almost always is the result of a
bacterial infection.3
Intrapartum transmission occurs around the time of labor
and delivery when the fetus passes through an infected birth
canal during vaginal delivery. This type of vertical trans-
mission can occur with herpes simplex virus6,7; intrapartum
transmission causes 85% of vertical herpes simplex virus
infections and is the basis for performing cesarean delivery
in infected mothers. Human papillomavirus and HIV can
also be transmitted to the infant through intrapartum
exposure during labor and delivery.8,9
Postpartum vertical transmission of viruses develops
following delivery. It can occur through contaminative
transmission of a virus from an infected mother via
respiratory secretions and fomites, skin-to-skin contact,
and breast milk. Respiratory viruses may be transmitted by
this mechanism, as well as those viral agents present in
breast milk, including HIV,10 cytomegalovirus,11 Ebola
virus,12 and others.
The large majority of infants born to pregnant women
with COVID-19 have been uninfected in China, the United
States, Europe, and all other regions where the pandemic is
occurring.13–19 The low rate of neonatal infection could be
expected based on data of vertical transmission existing with
other RNA respiratory viruses, including the coronaviruses
severe acute respiratory syndrome coronavirus and Middle
East respiratory syndrome coronavirus1 as well as influenza,
respiratory syncytial virus, parainfluenza, and human
metapneumovirus.1,2 The factors inherent in the observed
inhibition of respiratory RNA viruses from undergoing
intrauterine vertical transmission result from both viral and
host factors, and involve the ability of the virus to penetrate
the maternal-fetal interface including the placenta, avoiding
the innate immune system, and tropism of the virus to host
cells.2
Among the reported neonates who have had positive tests
for COVID-19, some have been asymptomatic,20–23 while
other neonates have had symptomatic illness.22,24 Among
symptomatic infants testing positive for COVID-19, there
has been variation in the onset of illness, ranging from
within 1 or 2 hours after delivery to within the first 24 to 72
hours of life and up to many days to weeks following
birth.13,23–25 Some of these cases have been considered to be
suspicious for vertical transmission, but the mechanisms
and timing for the neonate’s acquiring the infection have
remained unknown.
DETERMINING TRANSPLACENTAL TRANSMISSION
FROM THE ONSET OF NEONATAL ILLNESS
There is no agreed-upon definition of early-onset
neonatal COVID-19 infection. For bacterial infections such
as group B streptococcus and Escherichia coli, early-onset
neonatal sepsis is based upon timing of onset of either
bacteremia or bacterial meningitis, which in term infants is
less than 7 days of life. In preterm infants in the neonatal
intensive care unit, early-onset neonatal sepsis is defined as
occurring in the first 72 hours of life, and is generally
believed to be the result of bacterial agents transmitted
vertically from mother to infant before or during deliv-
ery.26,27 The majority (80%–90%) of early-onset neonatal
sepsis bacterial infections clinically present in the initial 24
to 48 hours following delivery.28
Zeng et al22 reported that among 33 neonates whose
mothers had COVID-19 infection in Wuhan, China, there
were 3 delivered by cesarean section who developed fever
and pneumonia and tested positive for the virus on the
second day of life. Although it might appear reasonable to
correlate the early onset of symptoms with vertical SARS-
CoV-2 infection and even intrauterine maternal-fetal
transmission in these cases and others, there are problems
with this assumption that would make it speculative for
several reasons.17 These include (1) symptoms such as
neonatal respiratory distress or pneumonia are not specific
to COVID-19—they can have multiple causes, and because
preterm delivery is present in between 37% and 63% of
infected neonates, it may have a noninfectious etiology that
is related to prematurity or is caused by infection by other
agents; (2) even in those cases where neonatal pneumonia
has radiographic features consistent with COVID-19 pul-
monary disease, its presence cannot be construed to result
specifically from transplacental viral transmission; (3) the
incubation period of COVID-19 following an initial fetal or
perinatal exposure to the virus is unknown; and (4) the exact
mechanism of transmission of SARS-CoV-2—transplacental
versus intrapartum—cannot be reliably distinguished by
either the presence or absence of neonatal symptoms in a
neonate with a positive reverse transcription (RT) polymer-
ase chain reaction (PCR) test for SARS-CoV-2.29–33 Thus, the
onset of symptoms shortly after birth in a neonate with early
positive testing for COVID-19 may be suggestive of vertical
transmission, but does not confirm a transplacental mech-
anism.
Determining Transplacental Transmission From Timing of
Neonatal Viral Testing by RT-PCR
The current gold standard for diagnosis of COVID-19 in
neonates is by RT-PCR analysis of specimens from
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nasopharyngeal (NP) swabs and, in lesser numbers of
infants, from swabs of the oropharynx. However, many
factors can affect the sensitivity (ability to detect a positive
case) and specificity (ability to determine a negative case) of
these tests. Reverse transcription polymerase chain reaction
analysis has many advantages for testing among children
and adults, but its efficacy for neonatal diagnosis has not
been established. Both analytical and external factors can
have a detrimental effect on the accuracy of RT-PCR results.
Preanalytical factors are the major source of errors in
laboratory testing and include problems due to the
specimen source, sampling methods, timing of sampling,
sample storage and transport, and presence of interfering
substances.34 The performance of diagnostic kits has been
reported in some cases to be suboptimal.34 In adult patients,
false-negative results have been demonstrated to be another
problem with RT-PCR.35,36
The Centers for Disease Control and Prevention37
recommends using NP swabs for molecular testing because
in most patients the major mechanisms of transmission of
COVID-19 are via the respiratory route and the nasophar-
ynx appears to have the highest concentration of virus.
However, in neonates, this has not been definitively
established. In fact, when the virus first appears in the
nasopharynx of neonates who are infected with SARS-CoV-
2 remains unknown. The mechanism(s) of NP colonization
by SARS-CoV-2 in cases of potential intrauterine or
intrapartum fetal infection also has not been determined,
especially in cases where the fetus may become infected
hematogenously via transplacental infection.
There has been significant variation in the timing of
SARS-CoV-2 positivity for NP and oropharyngeal speci-
mens taken from neonates. In some cases,24,38,39 specimens
taken shortly following birth were initially negative, to
subsequently become positive days or even weeks later. In
other cases,24,40 initial testing was positive in the late
neonatal period. Early positive testing for COVID-19 of
neonates from infected mothers has also been reported,17,22
in some cases with positive results obtained from specimens
taken immediately or within a few hours after birth.24,39 In
those cases of early test positivity, the neonates were
delivered by cesarean section, and as a result the possibility
of intrauterine vertical transmission remains high. However,
it cannot be confirmed based upon the information
available.
In a review of 179 newborn infants delivered to women
with COVID-19 during the third trimester, SARS-CoV-2
was detected from NP swabs in 6 infants—1 at 16 hours, 2 at
36 hours, and 3 at 48 hours following delivery—with the
authors stating that the timing of transmission could not be
determined in these cases.41
We propose that a neonate having a positive test for
SARS-CoV-2 in the initial 72 hours of life be considered to
have early-onset COVID-19 infection; it is this group of
neonates who are most suspicious for having acquired
COVID-19 from vertical transmission prior to or around the
period of delivery. The likelihood is even greater when the
initial testing is positive sooner—either immediately or
within hours after birth. To address this, we also propose the
term very early-onset COVID-19 infection for infants with test
positivity within the initial 24 hours of life. However, testing
positive for SARS-CoV-2 within these time frames does not
determine whether infection occurred via the transplacental
route.
DETERMINING TRANSPLACENTAL TRANSMISSION
FROM NEONATAL ANTIBODY ANALYSIS
Among all 5 classes of antibodies, immunoglobulin (Ig) G
is the only antibody class with the capability to cross the
placenta from the maternal to the fetal circulation, providing
passive immunity to the developing fetus and neonate. As a
result, the occurrence of elevated levels of IgG in the
newborn circulation following delivery is not useful for
diagnosing the acute onset of neonatal infection. Because
IgM does not cross the placenta, the concept of using
postpartum elevated levels of this antibody class to suggest
the possibility of intrauterine infections in neonates was
initially introduced in the 1960s.42,43 Currently, the majority
of congenital infections are not diagnosed using neonatal
IgM levels for several reasons. These include the propensity
for IgM assays to have reliability problems, including both
false-positive and false-negative results as well as cross-
reactivity and testing challenges, as well as technological
advances that have been made in the molecular diagnosis of
infectious diseases that have very high levels of sensitivity
and specificity.44,45
There have been several neonates delivered from SARS-
CoV-2–infected mothers who have had elevated levels of
specific IgG and IgM antibodies detected shortly after birth.
In one case,46 a newborn was found to have developed IgM
and IgG specific antibodies to SARS-CoV-2 together with
elevated cytokines when tested 2 hours following delivery,
but multiple NP swabs from the infant were negative for the
virus. In another report,22 2 neonates delivered to mothers
with COVID-19 were found to have levels of both IgG and
IgM that were higher than normal; both infants had NP
swabs that tested negative for COVID-19 by RT-PCR. These
cases demonstrate that using elevated IgM levels to
diagnose neonatal COVID-19, or to surmise that intrauter-
ine infection has occurred, is not highly reliable.
DETERMINING TRANSPLACENTAL TRANSMISSION
FROM VIRAL ANALYSIS OF SWABS OR HOMOGENIZED
WHOLE SAMPLES OF PLACENTA
The placenta is a unique heterogenous organ: it is
composed of cells from 2 genetically distinct individuals. It
is also distinctive in possessing a dual blood supply from 2
individuals: the maternal circulation enters the placenta
through numerous uterine spiral arterioles and circulates
within the intervillous space, and the fetal circulation enters
the placenta through the umbilical arteries and circulates
throughout all levels of the chorionic villus tree. These 2
circulations are in close contact with one another, but
remain separated by a highly specialized trophoblastic
barrier. In addition, both maternal and fetal cells are present
at the maternal-fetal interface. As a result, a sample of
placental tissue removed using a swab, needle, or excisional
biopsy contains both maternal and fetal cells, including
maternal red and white blood cells in the intervillous space.
Following homogenization of the tissue prior to nucleic acid
extraction, the maternal and fetal cells become mixed. A
positive PCR test for an infectious agent on a homogenized
sample of placental tissue or a swab of its contents
establishes that the agent is present in the sample, but
cannot precisely localize the agent to being in the maternal
component, the fetal component, or both. This is illustrated
in a recent communication47 in which swabs and biopsies
were taken from the placenta of a stillborn infant delivered
to a mother with COVID-19. These specimens were
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diagnosed using RT-PCR as being positive for SARS-CoV-2;
however, because the samples included cells of both
maternal and fetal origin, it was not possible to confirm
whether the coronavirus was in cells from the mother or the
fetus. Interestingly, despite the placental specimens testing
positive for COVID-19, amniotic fluid, maternal vaginal
swabs, and all specimens from the fetal autopsy, including
swabs from the mouth, axillae, meconium, and fetal blood,
obtained within minutes of birth were negative for SARS-
CoV-2 by RT-PCR testing. In another report,48 the amnionic
surface of the placenta was swabbed and found to be
positive for SARS-CoV-2 following delivery by an asymp-
tomatic mother with COVID-19. The neonate was asymp-
tomatic and uninfected. Thus, this form of placental
sampling and PCR analysis cannot reliably be used for
confirmation of transplacental viral transmission.
DETERMINING TRANSPLACENTAL TRANSMISSION
FROM ANATOMIC LOCALIZATION OF VIRAL SIGNAL
IN PLACENTAL TISSUE SECTIONS USING IN SITU PCR
OR IMMUNOHISTOCHEMISTRY
Pathology of the placenta, the largest of fetal organs, has
been instrumental in understanding the mechanisms of
transmission of many different infectious agents from
pregnant women to the fetus. Techniques such as immu-
nohistochemistry using antibodies to viral antigens and
nucleic acid techniques such as in situ hybridization and
RNAscope (Advanced Cell Diagnostics, Newark, California)
that detect target RNA molecules within intact cells have the
advantage of identifying virus within specific cell types in
defined anatomic compartments of the placenta.49,50 As a
result, these techniques can definitively localize a virus to
such fetal cells as the syncytiotrophoblast, Hofbauer cells
(fetal-derived villous stromal macrophages), extravillous
trophoblast, and chorionic villous endothelial cells. These
methods have been successfully used in past epidemics to
identify and confirm transplacental maternal-fetal viral
infection. In cases where both mother and neonate are
found to be infected, the placental finding of virus in such
chorionic villus cell types as syncytiotrophoblast using
immunohistochemistry for Ebola virus (Figure 1) or in
Hofbauer cells using an RNAscope in situ hybridization
methodology for Zika virus (Figure 2) can confirm
transplacental transmission of the pathogen.
The use of in situ hybridization was recently used to
identify and localize SARS-CoV-2 in the placentas from 2
infected neonates from Italy. In a study39 of 22 pregnant
women with COVID-19 at an Italian hospital, 2 neonates
were found to have positive NP swabs for SARS-CoV-2.
Placentas from both infants demonstrated chronic inter-
villositis, which was accompanied by the presence of CD-
68–positive macrophages in both the intervillous and the
villous space. The placental tissues were evaluated using in
situ hybridization with RNAscope technology, a method
that enables the detection of the SARS-CoV-2 spike protein
mRNA by using the V-nCoV2019-S probe (Advanced Cell
Diagnostics). In both placentas this methodology demon-
strated the presence of the coronavirus in the syncytiotro-
phoblast, indicating the presence of SARS-CoV-2 on the
fetal side of the placenta (Figure 3), and proving that
Figure 1. The placenta from a woman
having Ebola virus disease during pregnancy.
Both she and her newborn infant died from
the infection. Immunohistochemical analysis
demonstrates Ebola virus antigen in tropho-
blast (black arrow). This case and the
methodology for immunohistochemical stain-
ing were described by the Centers for Disease
Control and Prevention in Muehlenbachs et
al50 (immunohistochemistry using rabbit poly-
clonal antisera against Ebola virus, Sudan
virus, and Reston virus and Ebola virus
hyperimmune mouse ascitic fluid, original
magnification 3100).
Figure 2. Zika virus RNA (red arrow) is
positive by RNAscope in a stromal cell,
presumably a Hofbauer cell, in the chorionic
villus of the placenta of a preterm infant with
congenital Zika virus infection and micro-
cephaly (in situ hybridization for Zika virus,
original magnification 3100).
Figure 3. Brown dots represent positive signals from the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein mRNA
in this tissue section from a neonate with SARS-CoV-2 infection
following delivery from a mother with coronavirus disease 2019. The
pattern of RNAscope assay positivity confirms coronavirus infection of
the syncytiotrophoblast. This case and the methodology for RNAscope
staining were described by Patanè et al39 (in situ hybridization for SARS-
CoV-2, original magnification 3100).
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intrauterine infection of fetal cells within the placenta had
occurred in the intrauterine environment and prior to
delivery. This was the first demonstration of SARS-CoV-2
in chorionic villus tissue of the placenta of infected
neonates, establishing intrauterine fetal exposure and
infection with the coronavirus.
This communication proposes that the identification of
virus in chorionic villus tissue of the placenta, either using in
situ nucleic acid hybridization methods as performed by
Patanè and colleagues39 or by immunohistochemistry using
virus-specific antibodies to detect viral antigen, provides
prima facie evidence of intrauterine fetal infection in the
appropriate clinical setting.
CONCLUSIONS
Approximately 217 neonates delivered to pregnant
women with COVID-19 have been reported in the
literature.51 More recently, 19 additional infected neonates
were reported24 from 10 hospitals in Iran, among whom
there were infants with early and late positive testing for the
virus. The relative risks and proportions of neonatal
infections that result from a) intrauterine transmission of
SARS-CoV-2 from either transplacental or ascending
infection; b) acquiring infection during labor and delivery;
or c) following delivery from the mother, other individuals,
or the environment remain unknown. This knowledge is of
critical importance—it can guide management of pregnant
mothers with COVID-19, delivery, and postpartum care of
the neonate in order to minimize the risk of neonatal
infection. In addition, identifying mechanisms of neonatal
COVID-19 infection will be useful in determining such
factors as the need for cesarean delivery, neonatal isolation
in intensive care, guidelines for neonatal resuscitation, safety
of rooming-in, avoidance of skin-to-skin contact and
breastfeeding, and postpartum contact between the neonate
and family members and other individuals. Until these data
are established, there will continue to be variation in the
care of pregnant women with COVID-19 and their
neonates. Institutions, hospitals, professional organizations,
and the public health community have attempted to use the
limited data available to provide recommendations for
clinical care that reduces risk of neonatal infection within
the contexts of local social and clinical settings.50
In determining whether intrauterine vertical transmission
of SARS-CoV-2 has occurred, multiple findings are sugges-
tive; these include positive RT-PCR testing of a neonate for
the virus at or shortly after birth, early onset of symptoms,
and elevated levels of specific IgM antibodies following
delivery. However, confirmation of intrauterine transpla-
cental transmission of COVID-19 should be reserved for
those neonates who have demonstrable identification of
viral antigen or RNA in fetal-derived placental cells
following microscopic pathology testing of tissue sections.
These methods include using immunohistochemistry for
identification of viral antigen and detection of viral RNA
using in situ hybridization or RNAscope methods. It is clear
that many, if not most, pathology laboratories will not have
the capability of performing these types of tests on
placentas. However, it is suggested that whenever feasible,
placentas be retained from those neonates suspected of
having early-onset COVID-19 and, when necessary, have
formalin-fixed tissues sent to appropriate pathology labo-
ratories for special testing and evaluation of transplacental
infection. At this point in time, fortunately, it appears as
though bona fide transplacental transmission is highly
unusual.52
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